Searched for
KEYTRUDA
Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...- Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...
- Cancer drug price cuts leave costly brands untouchedPrices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices ...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leakModerna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline era...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepinessPharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adul...
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...
- Moderna, Merck breakthrough could usher in wave of cancer vaccinesMerck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target ...
- Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trialModerna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, redu...
- Merck & Co to create a separate cancer unit as patent cliff loomsMerck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-gr...
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...
- Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...
- Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatmentDr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...
- Big chase for a cancer drug: The urgent need for affordable Keytruda alternativesKeytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...
- mRNA technology-based Cancer vaccine boosts chances of survival: ModernaData revealed that using Merck's immunotherapy drug in combination with high-risk patients decreased their risk of dying.
- MSD launches blockbuster cancer drug Keytruda in IndiaDCGI gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and ...
- Breakthrough cancer drugs all set for India launchThe accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by ...
Load More
